Nelson Roberts Investment Advisors LLC Buys Shares of 740 Amgen Inc. (AMGN)

Nelson Roberts Investment Advisors LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 740 shares of the medical research company’s stock, valued at approximately $121,000.

Other large investors have also modified their holdings of the company. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new stake in shares of Amgen during the fourth quarter worth $102,000. Signature Estate & Investment Advisors LLC raised its stake in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares during the period. Finally, Focused Wealth Management Inc raised its stake in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares during the period. Hedge funds and other institutional investors own 78.87% of the company’s stock.

Amgen Inc. (NASDAQ AMGN) opened at 180.89 on Wednesday. The firm has a market cap of $133.03 billion, a price-to-earnings ratio of 17.18 and a beta of 1.36. The company’s 50-day moving average price is $170.78 and its 200-day moving average price is $165.90. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.84 EPS. Analysts predict that Amgen Inc. will post $12.48 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://sportsperspectives.com/2017/07/26/nelson-roberts-investment-advisors-llc-buys-shares-of-740-amgen-inc-amgn.html.

A number of equities research analysts have weighed in on the company. Cann restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research note on Wednesday. BMO Capital Markets restated a “buy” rating and set a $199.00 price objective on shares of Amgen in a research note on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a research note on Saturday. Credit Suisse Group set a $177.00 price objective on Amgen and gave the company a “hold” rating in a research note on Friday, July 14th. Finally, Jefferies Group LLC restated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and three have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $185.85.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply